Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce ...

R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its ...

Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.

Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for most solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Bristol Myers Squibb (BMY ... of a positive EPS surprise. This biopharmaceutical company is expected to post ...

PRINCETON, N.J., January 31, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Cantor Fitzgerald updated its financial model for Bristol-Myers Squibb Co. (NYSE:BMY), leading to an increased price target on the company's stock. Analysts at the firm now see the price target at $55 ...